Sareum Holdings PLC Sareum to Participate in the Edison Open House (8158M)

TIDMSAR

RNS Number : 8158M

Sareum Holdings PLC

26 January 2021

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Sareum to Participate in the Edison Open House: Global Healthcare 2021

Cambridge, UK, 26 January 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that its Chief Executive Officer, Dr Tim Mitchell, is participating today in a virtual interview at the Edison Open House: Global Healthcare 2021 event, taking place online between 26 and 28 January 2021.

Dr Mitchell's session will take place between 14:30 and 15:00 GMT on Tuesday 26 January.

The following link can be used to register: https://www.lsegissuerservices.com/spark/edison-open-house-global-healthcare-2021

For further information, please contact:

 
 Sareum Holdings plc 
  Tim Mitchell, CEO                         01223 497 700 
 Strand Hanson Limited (Nominated 
  Adviser) 
  James Dance / James Bellman               020 7409 3494 
 Hybridan LLP (Nominated Broker) 
  Claire Noyce / John Beresford-Peirse      020 3764 2341 
 Citigate Dewe Rogerson (Financial 
  PR) 
  Mark Swallow/ David Dible                 020 7638 9571 
 

About EOP:GH 2021

The Edison Open House: Global Healthcare 2021 (EOP:GH 2021) is a virtual conference with a mission - to open up access to the booming universe of healthcare stocks to the widest possible audience.

The event will explore the case for investing in a carefully curated selection of microcap stocks - as well as demystify the global megatrends behind the boom in healthcare investment which, in the third quarter of last year alone, saw a record GBP1 billion raised in the UK.

Thousands of institutions, family offices, wealth managers and individual investors - as well journalists, entrepreneurs and investment banks - will be hosted across the three days.

EOP:GH 2021 was created by Edison and is brought to you in partnership with the Spark Live, the streaming platform from London Stock Exchange Group (LSEG) , and law firm Taylor Wessing .

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCQELFLFFLXBBX

(END) Dow Jones Newswires

January 26, 2021 02:00 ET (07:00 GMT)